Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NAVB news,
http://finance.yahoo.com/news/navidea-biopharmaceuticals-submits-lymphoseek-marketing-143000444.html
Navidea Biopharmaceuticals Submits Lymphoseek Marketing Authorization Application to European Medicines Agency
This paragraph is also very important:(Good for our FDA)
"It is also important to note that, as part of the normal MAA filing process, the EMA required good manufacturing practices (GMP) pre-submission inspections at the Lymphoseek contract manufacturing facilities. These inspections were recently successfully completed by independent auditors from the European Union (EU), thereby enabling our MAA filing,” commented Dr. Mark Pykett, President and CEO of Navidea. “We are encouraged by these positive pre-submission manufacturing audits which we believe bode well for Lymphoseek’s ultimate commercialization. "
NAVB news,
http://finance.yahoo.com/news/navidea-biopharmaceuticals-submits-lymphoseek-marketing-143000444.html
Navidea Biopharmaceuticals Submits Lymphoseek Marketing Authorization Application to European Medicines Agency
This paragraph is also very important:(Good for our FDA)
"It is also important to note that, as part of the normal MAA filing process, the EMA required good manufacturing practices (GMP) pre-submission inspections at the Lymphoseek contract manufacturing facilities. These inspections were recently successfully completed by independent auditors from the European Union (EU), thereby enabling our MAA filing,” commented Dr. Mark Pykett, President and CEO of Navidea. “We are encouraged by these positive pre-submission manufacturing audits which we believe bode well for Lymphoseek’s ultimate commercialization. "
MMRF-Here is a deal recognizing MMRF's patent portfolio from a COMPETITOR-
" In spite of the fact that our two companies regularly compete in the marketplace , we recognize the importance of MMR's Patent Portfolio as we approach requirements under the HITECH Act mandating the use of Personal Health Records and Patient Portals by 2014 . Therefore , for the benefit of our
clients and shareholders , we have made the decision to license the technology at this time."
MMRGlobal Inks Royalty - Based License Agreement With Electronic Health Record
Provider Healthcare Holdings Group and PHR Competitor Access My Records
LOS ANGELES , CA -- ( Marketwire ) -- 12 / 18 / 12 -- MMRGlobal , Inc . ( OTCQB : MMRF )
today announced it has filed a Form 8 - K regarding the signing of another
royalty - based licensing agreement . On December 17 , 2012 , MyMedicalRecords ,
Inc . (" MMR ") signed a Non - Exclusive Patent License Agreement with Healthcare
Holdings Group , Inc . (" HCH ") , the parent of Access My Records , Inc . , to
license the U . S . rights for the health IT patents owned by MyMedicalRecords ,
Inc . These include but are not limited to U . S . Patent Numbers 8 , 321 , 240 ;
8 , 301 , 466 ; 8 , 117 , 045 ; 8 , 117 , 646 ; and 8 , 121 , 855 , as well as any other health IT
patents to be issued pursuant to pending applications filed by
MyMedicalRecords in the United States and all divisions , continuations ,
reissues , and extensions ( the " MMR Patents "). The initial term of the
Agreement is five years and automatically renews to the expiration date of the
last licensed patent to expire , which currently in the U . S . is twenty years
from the date of filing . MMRGlobal is a leading provider of Personal Health
Records ( PHRs ) including its MyMedicalRecords . com PHR and MMRPro document
management and imaging systems for healthcare professionals .
According to Robert H . Lorsch , MMRGlobal Chairman and CEO , " We are pleased
that we have been able to announce royalty - based license agreements with EHR
vendors , surgery centers , and now a PHR vendor , in addition to entering into
relationships with retailers and others as a direct result of the Company ' s
patented IP in our products and services . As a result of recently issued
patents and Notices of Allowance , we are continuing to discuss other licensing
relationships with hospitals , physician groups , retail pharmacies , patient
monitoring and telemedicine service providers and laboratories , as well as
other software and equipment vendors in the healthcare and wellness markets ."
Healthcare Holdings Group , Inc . is a comprehensive Electronic Health Record
systems provider . HCH ' s solutions are designed for General Practice and
Chiropractic disciplines . The company ' s software systems include ChartZoneMD ,
an EHR cloud - based software solution , and SmartFormsMD , a Voice Recognition
Medical Dictionary module . HCH , through its wholly - owned operating subsidiary ,
Access My Records , Inc . , provides the AccessMyRecords . com Personal Health
Record and a free - standing Patient Portal designed to seamlessly connect to
any EHR system .
" We have been following MyMedicalRecords ' efforts to provide untethered
standardized solutions to how patients share medical information with their
doctors , " said Leonard Tambasco , Chairman and CEO of Healthcare Holdings
Group , Inc . " In spite of the fact that our two companies regularly compete in
the marketplace , we recognize the importance of MMR ' s Patent Portfolio as we
approach requirements under the HITECH Act mandating the use of Personal
Health Records and Patient Portals by 2014 . Therefore , for the benefit of our
clients and shareholders , we have made the decision to license the technology
at this time . Although we approach the market differently , we both have a
mission to provide seamless connectivity between patients and physicians . The
Agreement with MMR is consistent with HCH ' s position to enhance and support
industry - wide standardization efforts . HCH will launch its MU - 1 compliant EHR
at HIMSS 13 ."
About MMRGlobal MMRGlobal , Inc . , through its wholly - owned operating
subsidiary , MyMedicalRecords , Inc . , provides secure and easy - to - use online
Personal Health Records (" PHRs ") and electronic safe deposit box storage
solutions , serving consumers , healthcare professionals , employers , insurance
companies , financial institutions , and professional organizations and affinity
groups . The MyMedicalRecords PHR enables individuals and families to access
their medical records and other important documents , such as birth
certificates , passports , insurance policies and wills , anytime from anywhere
using the Internet . MyMedicalRecords is built on proprietary , patented
technologies to allow documents , images and voicemail messages to be
transmitted and stored in the system using a variety of methods , including
fax , phone , or file upload without relying on any specific electronic medical
Healthcare Holdings Group , Inc . ( HCH ) provides the Electronic Health Records
( EHR ) software suite , ChartZoneMD , designed to give physicians ' offices an
easy and cost - effective cloud - based practice management solution .
ChartZoneMD ' s suite of applications , tools , and technology allow clinicians to
seamlessly transit from paper charts to the recently mandated Meaningful Use
EHR format and reporting styles . In addition , HCH has developed SmartFormsMD ,
a free - standing , time - saving , error - reducing , customizable , medical
voice - command module complete with medical dictionary integration and
specialty accommodation . The ChartZoneMD Software Suite enables real - time
sharing of medical records with patients via the Access My Records integrated
patient - portal module . For more information , visit
www . healthcareholdingsgroup . com .
Forward - Looking Statements
All statements in this press release that are not strictly historical in
nature including , without limitation , management ' s expectations , beliefs ,
intentions , estimates or projections , constitute " forward - looking statements ."
Such forward - looking statements involve known and unknown risks , uncertainties
and other factors that may cause the Company ' s actual results to be materially
different from historical results or from any results expressed or implied by
such forward - looking statements . Some can be identified by the use of words
( and their derivations ) such as " need , " " possibility , " " potential , " " intend , "
" offer , " " development , " " if , " " negotiate , " " when , " " begun , " " believe , "
" achieve , " " will , " " estimate , " " expect , " " maintain , " " plan , " and " continue , "
or the negative of these words . Results of operations and the timing of
selected events may differ materially from the results predicted , and any
reported results should not be considered as an indication of future
performance . Such statements are necessarily based on assumptions and
estimates and are subject to various risks and uncertainties , including those
relating to the possible invalidity of the underlying assumptions and
estimates and possible changes or developments in economic , business ,
industry , market , legal and regulatory circumstances and conditions and
actions taken or omitted to be taken by third parties , including customers ,
suppliers , business partners , potential licensees , competitors and
legislative , judicial and other governmental authorities and officials .
Factors that could cause or contribute to such differences include , but are
not limited to : actual or unexpected outcomes with respect to intellectual
property enforcement actions , claims of intellectual property infringement and
general intellectual property litigation or licensing transactions ; our
ability to maintain , develop , monetize and protect our patent portfolio for
both the Company ' s health IT and biotechnology intellectual property assets in
the U . S . and internationally ; our ability to establish and maintain strategic
relationships ; changes in our relationships with our licensees ; the risk the
Company ' s products are not adopted or viewed favorably by the healthcare
community and consumer retail market ; business prospects , results of
operations or financial condition ; risks related to the current uncertainty
and instability in financial and lending markets , including global economic
uncertainties ; the timing and volume of sales and installations ; the length of
sales cycles and the installation process ; the market ' s acceptance of new
product and service introductions ; competitive product offerings and
promotions ; changes in government laws and regulations and future changes in
tax legislation and initiatives in the healthcare industry ; undetected errors
in our products ; the possibility of interruption at our data centers ; risks
related to third party vendors ; risks related to obtaining and integrating
third - party licensed technology ; risks related to a security breach by third
parties ; risks associated with recruitment and retention of key personnel ;
other litigation matters ; uncertainties associated with doing business
internationally across borders and territories ; and additional risks discussed
in the Company ' s filings with the Securities and Exchange Commission . The
Company is providing this information as of the date of this release and ,
except as required by applicable law , does not undertake any obligation to
update any forward - looking statements contained in this release as a result of
new information , future events or otherwise .
J B I I,
Just Beat It Indefinitely.
Manny
All those exercise of stock options,and the latest buy of 14,000 shares at 7.6 by a Director,should give people confidence in holding.
http://www.secform4.com/insider-trading/749647.htm
The Market maker EDGX who has been throwing shares at CLSN to keep it from rising,has gotten some help from The Street.
Hopefully,once again, he will be swamped again with buys.
Manny
I am surprised you lasted this long with Schwab on OTC/Pinks.
UBSS,their Market maker are big crooks.Why should they give you the trade,if they can get paid for getting you a trade for a fee at other brokerages.
I stopped trading OTC/Pinks with them.
TD Ameritrade has not been much better lately.I am trying to avoid these kind of stocks that cause nothing but aggravation.
Manny
ZGNX,
Major Insider buys.
Director buys 70,000 shares at 1.21.He(She) now owns 296,750 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8609007
Chief Development Officer buys 50,000 shares at 1.17.She now owns 52,746 shares.
http://www.secform4.com/insider-trading/1375151.htm
Manny
ZGNX,
Major Insider buys.
Director buys 70,000 shares at 1.21.He(She) now owns 296,750 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8609007
Chief Development Officer buys 50,000 shares at 1.17.She now owns 52,746 shares.
http://www.secform4.com/insider-trading/1375151.htm
Manny
ZGNX,
CFO,Treasuer &Secretary buys 17,500 shares at 1.19.He now owns 150,742 shares.
http://www.secform4.com/insider-trading/1375151.htm
Manny
See if you can hang around for when Platinum-Montaur votes all their shares for the company to be bought out.
Manny
NAVB,
Gets financing from Platinum Montaur,their biggest shareholder.
Navidea Biopharmaceuticals Provides Financing Update - Company accesses line of credit to support ongoing development plans.
http://www.marketwatch.com/story/navidea-biopharmaceuticals-provides-financing-update-2012-12-11
NAVB,
Gets financing from Platinum Montaur,their biggest shareholder.
Navidea Biopharmaceuticals Provides Financing Update - Company accesses line of credit to support ongoing development plans.
http://www.marketwatch.com/story/navidea-biopharmaceuticals-provides-financing-update-2012-12-11
MMRF,
Today's volume- 4,752,500.
Avg Vol (3 month)3: 900,156
Avg Vol (10 day)3: 3,583,000
http://finance.yahoo.com/q/ks?s=MMRF+Key+Statistics
Manny
CUR,
Neuralstem: Evidence Of Long-Term Cell Survival
Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND
Evidence of Long-Term Cell Survival 12/10 09:15 AM
NIH Funding for Phase II
ROCKVILLE, Md., Dec. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (CUR:...) announced that Jonathon Glass, MD, Director of the Emory ALS Center, presented new data from the Phase I trial of Neuralstem (CUR:...) 's human spinal cord stem cells, NSI-566, in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the International Symposium on ALS/MND in Chicago, sponsored by the Motor Neurone Disease Association. In a Thursday presentation, "RESULTS OF PHASE 1 TRIAL OF SPINAL CORD TRANSPLANTATION OF NEURAL PROGENITOR CELLS IN ALS (THE NEURALSTEM, INC. (CUR:...) TRIAL)," Dr. Glass revealed that researchers were able to establish the long-term survival of Neuralstem (CUR:...) 's transplanted spinal cord stem cells in autopsied patients, through a technology called DNA fingerprinting. Dr. Glass, who is the principal site investigator of the trial at Emory, also announced that the study team has received a grant from the National Institutes of Health (NIH) to cover a majority of the cost of an upcoming Phase II trial.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
"We are quite pleased by our ability to perform all of the surgeries planned for the Phase I trial without evidence of significant surgical or medical complications, including those patients who received both lumbar and cervical transplantations," said Dr. Glass. "We can also report that we found evidence of cell survival in all of the patients who came to autopsy, including our first patient who died 30 months after transplantation.
This is very positive news, supporting our plan to accelerate this study by increasing the dose of stem cells delivered to the cervical spinal cord in the hopes of delaying respiratory failure and prolonging life. The next phase of the study has been partially funded by a generous grant from the National Institutes of Health, and we will begin once the FDA approves our new protocol," Dr. Glass concluded.
"This is a major finding," said Karl Johe, Ph.D., Neuralstem (CUR:...) Chairman of the Board and Chief Scientific Officer. "There is currently no way to confirm the survival of the cells in patients while they are alive. Levels of functional recovery, or a slowdown in the progression of the disease in various patients, have given us reason to believe the cells have survived. Now, cell survival has been demonstrated by definitive evidence.
Among the six patients autopsied (five died of ALS disease progression and one, of unrelated heart failure), the survival period, from stem cell transplantation to death, ranged from 196 – 921 days. Five of these patients had discontinued all immune suppression medications for 57 – 638 days prior to death, but showed the stem cell DNA content in the range of 0.67% - 5.4% of total DNA in some spots of cord treated with the stem cells. There was no correlation of DNA content to survival period without immune suppression medication. These data, therefore, suggest that long-term immuno suppression of patients is not required for long-term survival of our cells, which points towards the feasibility of needing only transient immune suppression in future ALS trials," Dr. Johe concluded.
About Neuralstem (CUR:...)
Neuralstem (CUR:...) 's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem (CUR:...) has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.
Neuralstem (CUR:...) also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem (CUR:...) has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem (CUR:...) 's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem (CUR:...) 's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended September 30, 2012.
SOURCE Neuralstem, Inc. (CUR:...)
CUR,
Neuralstem: Evidence Of Long-Term Cell Survival
Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND
Evidence of Long-Term Cell Survival 12/10 09:15 AM
NIH Funding for Phase II
ROCKVILLE, Md., Dec. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (CUR:...) announced that Jonathon Glass, MD, Director of the Emory ALS Center, presented new data from the Phase I trial of Neuralstem (CUR:...) 's human spinal cord stem cells, NSI-566, in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the International Symposium on ALS/MND in Chicago, sponsored by the Motor Neurone Disease Association. In a Thursday presentation, "RESULTS OF PHASE 1 TRIAL OF SPINAL CORD TRANSPLANTATION OF NEURAL PROGENITOR CELLS IN ALS (THE NEURALSTEM, INC. (CUR:...) TRIAL)," Dr. Glass revealed that researchers were able to establish the long-term survival of Neuralstem (CUR:...) 's transplanted spinal cord stem cells in autopsied patients, through a technology called DNA fingerprinting. Dr. Glass, who is the principal site investigator of the trial at Emory, also announced that the study team has received a grant from the National Institutes of Health (NIH) to cover a majority of the cost of an upcoming Phase II trial.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
"We are quite pleased by our ability to perform all of the surgeries planned for the Phase I trial without evidence of significant surgical or medical complications, including those patients who received both lumbar and cervical transplantations," said Dr. Glass. "We can also report that we found evidence of cell survival in all of the patients who came to autopsy, including our first patient who died 30 months after transplantation.
This is very positive news, supporting our plan to accelerate this study by increasing the dose of stem cells delivered to the cervical spinal cord in the hopes of delaying respiratory failure and prolonging life. The next phase of the study has been partially funded by a generous grant from the National Institutes of Health, and we will begin once the FDA approves our new protocol," Dr. Glass concluded.
"This is a major finding," said Karl Johe, Ph.D., Neuralstem (CUR:...) Chairman of the Board and Chief Scientific Officer. "There is currently no way to confirm the survival of the cells in patients while they are alive. Levels of functional recovery, or a slowdown in the progression of the disease in various patients, have given us reason to believe the cells have survived. Now, cell survival has been demonstrated by definitive evidence.
Among the six patients autopsied (five died of ALS disease progression and one, of unrelated heart failure), the survival period, from stem cell transplantation to death, ranged from 196 – 921 days. Five of these patients had discontinued all immune suppression medications for 57 – 638 days prior to death, but showed the stem cell DNA content in the range of 0.67% - 5.4% of total DNA in some spots of cord treated with the stem cells. There was no correlation of DNA content to survival period without immune suppression medication. These data, therefore, suggest that long-term immuno suppression of patients is not required for long-term survival of our cells, which points towards the feasibility of needing only transient immune suppression in future ALS trials," Dr. Johe concluded.
About Neuralstem (CUR:...)
Neuralstem (CUR:...) 's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem (CUR:...) has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.
Neuralstem (CUR:...) also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem (CUR:...) has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem (CUR:...) 's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem (CUR:...) 's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended September 30, 2012.
SOURCE Neuralstem, Inc. (CUR:...)
CLSN,
CEO exercises 17,271 shares at 2.77.He had till 11/25/2017 to exercise.He now owns 213,285 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8598081
Manny
CLSN,
CEO exercises 17,271 shares at 2.77.He had till 11/25/2017 to exercise.He now owns 213,285 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8598081
Manny
CLSN,
Director exercises 34,583 shares at 3.25 per share.he now owns 156,625 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8596180
Manny
CORT,
Keeps going up.Traded as high as 1.80 in regular trading.Has traded at 1.84 in after hours.
Another buy by the Director Leonard Baker who is a 10% plus owner.This time 87,131 shares at average 1.461 in a few Irrevocable Trusts.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8597418
http://www.secform4.com/insider-trading/1088856.htm
Manny
CORT,
Keeps going up.Traded as high as 1.80 in regular trading.Has traded at 1.84 in after hours trading.
Another buy by the Director Leonard Baker who is a 10% plus owner.This time 87,131 shares at average 1.461 in a few Irrevocable Trusts.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8597418
http://www.secform4.com/insider-trading/1088856.htm
Manny
AUGT-Hipcricket Performance Drives Three-Year Contract Extension With Griffin Communications
Hipcricket®, Inc. ("Hipcricket"), the one-stop mobile advertising and marketing and subsidiary of Augme® Technologies, Inc. (OTCBB: AUGT) (or "Augme"), today announced that it has signed a three-year renewal with Griffin Communications L.L.C., which provides statewide coverage through television stations in Oklahoma City and Tulsa. The agreement extends the broadcast company's outreach to viewers via any mobile platform or device with such vital information as school closures and severe weather targeted to a listener's zip code.
Griffin Stations News 9 in Oklahoma City and News On 6 in Tulsa provide a variety of opt-in alerts including local, national or international breaking news, weather forecasts and alerts, school closures, high school and college football scores, and morning and afternoon headlines.
Since March 2009, the stations have increased time spent viewing (TSV) by opting in Oklahomans to receive programming information they seek. Griffin entities have also monetized the mobile efforts through keyword driven client sales promotions and advertiser or station sponsored campaigns.
"Part of our mission at Griffin Communications is to deliver timely, useful news and information relevant to the passions of Oklahomans, accessible through any device: TV, radio, Web, mobile," said Kevin Fullbright, Griffin Communications Vice President of New Media. "Hipcricket expertly enables us to fulfill our mission."
"We appreciate the loyalty shown by our partners at Griffin," said Doug Stovall, Hipcricket Executive Vice President - Sales and Services. "Mobile connects Griffin with its viewers in personal ways and is often the 'go-to' tool when the weather turns bad or the family wants a sports score from Oklahoma's high school or college teams."
About Hipcricket
Hipcricket, Inc., a wholly-owned subsidiary of Augme Technologies, Inc. (OTCBB: AUGT), is the one-stop mobile advertising and marketing company that empowers brands, agencies and media properties to engage customers, drive loyalty and increase sales. Hipcricket's customers connect with consumers across every mobile channel, including SMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Hipcricket's proven technology, strategic and marketing services and experienced account management teams have provided measurable success to a broad range of national and regional brand-name leaders (e.g., Macy's, MillerCoors, Clear Channel) across an industry-leading 225,000+ campaigns. The company has also created the first comprehensive mobile ad network that taps into the buying power of the mass market with industry-leading capabilities to target customers via location and highly-specific demographic information across SMS, display, rich media and video.
Hipcricket is based in New York, with operations in Seattle, Dallas, Chicago, Atlanta, Los Angeles, San Francisco and Miami.
About Griffin Communications
Griffin Communications, L.L.C. is an Oklahoma-owned multimedia company, providing news and information content to Oklahomans across the state. Holdings include KWTV/News 9 in Oklahoma City and KOTV/News On 6 and KQCW/The Tulsa CW in Tulsa. Griffin's holdings also include News9.com, NewsOn6.com, and Radio Oklahoma Network, representing 40+ affiliates across Oklahoma. Griffin Communications also has developed several partnerships and strategic alliances throughout Oklahoma, including Oklahoma Community Television/Griffin Tower Company, Sooner Sports Properties and News 9 Now/News On 6 Now (Cox Communications). Griffin Communications, L.L.C. is among a few privately held media companies in the country, owned by David and Kirsten Griffin of Oklahoma City, and John Griffin of Muskogee. Griffin Communications, L.L.C. solely focuses its resources in the state of Oklahoma -- Oklahoma businesses owned and operated by Oklahomans.
Contact:
Hipcricket, Inc.
pr@hipcricket.com
CORT,
Closed at 1.65,up 9.72%.
Once again there was a volume spike of close to 200,000 shares and the stock shot up from 1.59 to 1.69.
Today,unlike the other 2 spike days the stock price closed at 1.65, much closer to the 1.70 spike high of the day than the other days' closes.
http://finviz.com/quote.ashx?t=cort&ty=c&ta=1&p=d
Manny
CORT,
Closed at 1.65,up 9.72%.
Once again there was a volume spike of close to 200,000 shares and the stock shot up from 1.59 to 1.69.
Today,unlike the other 2 spike days the stock price closed at 1.65, much closer to the 1.70 spike high of the day than the other days' closes.
http://finviz.com/quote.ashx?t=cort&ty=c&ta=1&p=d
Manny
MMRF,
Volume at 7 million shares is is now more than 4 1/2 times the ten day average of 1.578 million.
STSI,
Tradewinds Investment Mgmt exercises 1,290,323 shares at 1 dollar.They now control 23,231,111 shares
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8594277
Manny
STSI,
Tradewinds Investment Mgmt exercises 1,290,323 shares at 1 dollar.They now control 23,231,111 shares
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8594277
Manny
MMRF,
Volume of 5.3 million, is already 3 1/2 times the ten day average volume of 1.578 million,after only 2 hours 15 minutes of trading.
Dec 4, 2012 0.02 0.02 0.02 0.02 4,931,800 0.02
Dec 3, 2012 0.02 0.02 0.02 0.02 1,701,300 0.02
Nov 30, 2012 0.02 0.02 0.02 0.02 70,900 0.02
Nov 29, 2012 0.01 0.02 0.01 0.02 105,200 0.02
Nov 28, 2012 0.02 0.02 0.01 0.01 3,924,300 0.01
Nov 27, 2012 0.02 0.02 0.01 0.01 194,600 0.01
Nov 26, 2012 0.02 0.02 0.02 0.02 119,500 0.02
Nov 23, 2012 0.02 0.02 0.02 0.02 7,000 0.02
Nov 21, 2012 0.02 0.02 0.02 0.02 6,400 0.02
Nov 20, 2012 0.02 0.02 0.02 0.02 152,800 0.02
Nov 19, 2012 0.01 0.02 0.01 0.02 187,100 0.02
Nov 16, 2012 0.02 0.02 0.01 0.02 615,400 0.02
Nov 15, 2012 0.02 0.02 0.02 0.02 606,600 0.02
Nov 14, 2012 0.02 0.02 0.01 0.02 565,200 0.02
Nov 13, 2012 0.02 0.02 0.01 0.02 2,587,700 0.02
Nov 12, 2012 0.02 0.02 0.02 0.02 808,700 0.02
Nov 9, 2012 0.02 0.02 0.02 0.02 771,200 0.02
Nov 8, 2012 0.02 0.02 0.02 0.02 1,003,200 0.02
Nov 7, 2012 0.02 0.02 0.02 0.02 230,200 0.02
Nov 6, 2012 0.02 0.02 0.02 0.02 1,147,200 0.02
Nov 5, 2012 0.02 0.02 0.02 0.02 1,024,000 0.02
Nov 2, 2012 0.02 0.02 0.02 0.02 434,200 0.02
Nov 1, 2012 0.02 0.02 0.02 0.02 1,194,200
MMRF,
Volume of 5.3 million, is already 3 1/2 times the ten day average volume of 1.578 million,after only 2 hours 15 minutes of trading.
Dec 4, 2012 0.02 0.02 0.02 0.02 4,931,800 0.02
Dec 3, 2012 0.02 0.02 0.02 0.02 1,701,300 0.02
Nov 30, 2012 0.02 0.02 0.02 0.02 70,900 0.02
Nov 29, 2012 0.01 0.02 0.01 0.02 105,200 0.02
Nov 28, 2012 0.02 0.02 0.01 0.01 3,924,300 0.01
Nov 27, 2012 0.02 0.02 0.01 0.01 194,600 0.01
Nov 26, 2012 0.02 0.02 0.02 0.02 119,500 0.02
Nov 23, 2012 0.02 0.02 0.02 0.02 7,000 0.02
Nov 21, 2012 0.02 0.02 0.02 0.02 6,400 0.02
Nov 20, 2012 0.02 0.02 0.02 0.02 152,800 0.02
Nov 19, 2012 0.01 0.02 0.01 0.02 187,100 0.02
Nov 16, 2012 0.02 0.02 0.01 0.02 615,400 0.02
Nov 15, 2012 0.02 0.02 0.02 0.02 606,600 0.02
Nov 14, 2012 0.02 0.02 0.01 0.02 565,200 0.02
Nov 13, 2012 0.02 0.02 0.01 0.02 2,587,700 0.02
Nov 12, 2012 0.02 0.02 0.02 0.02 808,700 0.02
Nov 9, 2012 0.02 0.02 0.02 0.02 771,200 0.02
Nov 8, 2012 0.02 0.02 0.02 0.02 1,003,200 0.02
Nov 7, 2012 0.02 0.02 0.02 0.02 230,200 0.02
Nov 6, 2012 0.02 0.02 0.02 0.02 1,147,200 0.02
Nov 5, 2012 0.02 0.02 0.02 0.02 1,024,000 0.02
Nov 2, 2012 0.02 0.02 0.02 0.02 434,200 0.02
Nov 1, 2012 0.02 0.02 0.02 0.02 1,194,200
I will probably sell half before 3.5 from my 2.08 average,and hope for great news on the rest.
Manny?
You still waiting for 2 dollars?
Manny
AUGT,
Directors get stock options for 6,000 shares at current value of .60.
This is a 3,600 dollar value,which will vest in 36 months.at 1/36 per month.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8591897
I would like to think that the company believes this will be worth much more in coming months,because this is one of the cheapest rewardsI have seen.
Manny
CORT,
Somebody is accumulating shares,and is willing to pay much higher.
Today was the second day in which there was a volume and price spike .Today, price was up as high as 1.75,or 28% on 219,000 shares,only to close at 1.55 or 9.93%.
Last week the price went up to 1.60 from a 1.39 open on a volume spike of 160,000 shares,only to close at 1.48.
http://finviz.com/quote.ashx?t=cort&ty=c&ta=1&p=d
Manny
CORT,
Somebody is accumulating shares,and is willing to pay much higher.
Today was the second day in which there was a volume and price spike .Today, price was up as high as 1.75,or 28% on 219,000 shares,only to close at 1.55 or 9.93%.
Last week the price went up to 1.60 from a 1.39 open on a volume spike of 160,000 shares,only to close at 1.48.
http://finviz.com/quote.ashx?t=cort&ty=c&ta=1&p=d
Manny
CORT,
219,000 shares traded in a 5 minute stretch that took price from 1.49 to 1.75.It is now 1.59.
Who is buying at these higher prices?
Manny
CORT,
219,000 shares traded in a 5 minute stretch that took price from 1.49 to 1.75.It is now 1.59.
Who is buying at these higher prices?
Manny
The Market Maker EDGX seems to be a big Short on many stocks that I follow.
I saw a 72,000 share offer by EDGX at around 3.03 or 3.04,which did not trade and quickly disappeared as the stock started moving higher.
Stock now is 3.09 by 3.10,so it looks like with Market cooperation(I hope without) we move higher.
Manny
Yes,
Those 5 cents dividends and 10 cents bonus showing up in my account really looks fraudulent.
lol,
Manny
Why can't you transfer them to another broker by end of December,then sell
Manny
I didn't find a company name for John J. McKeon's filing of an 8.3% ownership of STSI.Why is he so big in STSI?
This was my post earlier.
Who is this John Joseph McKeon that filed a 13G for ownership of 8.3% of STSI?
Google shows an Orthopedic Surgeon by that name.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8586361
Manny
STSI,
Who is this John Joseph McKeon that filed a 13G for ownership of 8.3% of STSI?
Google shows an Orthopedic Surgeon by that name.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8586361
Manny